Fig. 5

GLP-1R silencing abolished the azoramide (Azo) regulatory effects of suppressing C3H10T1/2 cell osteoblast differentiation and promoting their differentiation into adipocytes. a–c Alkaline phosphatase (ALP) staining and quantification subject to azoramide with or without glucagon-like peptide-1 receptor (GLP-1R) knock-down. Scale bar = 100 μm. d–f Real-time qPCR of Runt-related transcription factor 2 (Runx2), peroxisome proliferator-activated receptor gamma (PPARγ), and fatty acid binding protein 4 (Fabp4) mRNA in C3H10T1/2 cells subjected to different treatments. g–i Western blot of Runx2, PPARγ, and Fabp4 proteins in C3H10T1/2 cells subjected to different treatments. Bars represent the protein quantitative data normalized to β-actin. *p < 0.05, **p < 0.01, versus control (Con); ^#p < 0.05, ^##p < 0.01, versus Azo. si small interfering